After six months of injection, Gilead's scientific new drug for AIDS prevention was approved by the FDA. The HIV-1 capsid inhibitor Yeztugo has become the first and only HIV prevention regimen that requires only two doses per year. Based on Phase 3 research data, after administering Yeztugo twice a year, over 99.9% of participants remained HIV negative. This should be considered a major breakthrough in the fight against HIV. How many times should GILD's stock price not increase? Worth paying attention to